Are genomic stocks a good investment?

Genomics stocks can be good investments since they often have high growth potential. They tend to be volatile and risky, though, and many genomics companies spend years operating at a loss. It only makes sense to invest in genomics stocks if you have knowledge of the industry or are willing to do plenty of research to learn about it.

Who is the leading genomics company?

Natera was the leading genomics company by market cap as of April 2026.

Is genomics a growing field?

Yes, genomics is a growing field. Mordor Intelligence is forecasting that the genomics market will grow by 11.4% per year through 2031.

What is the future of genomic stocks?

Top genomics stocks could outperform the market as genetic analysis and genetic testing become more common. Technological advancements have lowered costs and made these treatments more accessible, which should allow more genomics companies to turn a profit.

What should I look for in a good genomics stock?

To evaluate a genomics stock, look at the treatments the company offers, its current stage of development in each one, and the results of previous clinical trials. Check the company's financials as well to see whether it's making money and is profitable. Many genomics companies aren't profitable, so this isn't always a reason to avoid a stock, but you should see how much it's spending and how long it can fund operations with its current cash reserves.

Can genomics stocks be part of a diversified portfolio?

Yes, genomics stocks can be part of a diversified portfolio. However, because these tend to be volatile, high-risk stocks, be careful about how much you invest. Consider starting with no more than 5% of your portfolio in genomics companies to limit your risk.

Which sectors benefit the most from genomics advancements?

The healthcare sector typically benefits most from genomic advancements, as they can improve medicine and patient care. Agriculture also benefits, with advances in genomics resulting in higher crop yields and more nutritious food.

Should beginners invest in genomics stocks?

No, because genomics stocks are generally complex, high-risk investments. They're more appropriate for advanced investors and those who know the genomics industry. Beginners interested in this industry could consider a genomics or healthcare ETF instead, or carefully research the genomics stocks of interest.

Best Genomics Stocks for 2026 and How to Invest

By Lyle Daly – Updated Apr 18, 2026 at 2:56 AM EST | Fact-checked by Frank Bass

Key Points

Natera uses AI to boost test accuracy and decision-making in health diagnostics.
Quest Diagnostics shows strong financial health with a rising net income and dividend payouts.
Krystal Biotech achieved profitability with FDA-approved treatments for rare diseases.

Genomics stocks are companies that study genes to improve people's lives. These companies generally fall into one of three categories: genetic sequencing and analysis, genetic testing and diagnosis, and genetic editing.

With technological advancements dramatically improving the cost, accuracy, and time to map a person’s entire genome, many rapidly growing companies are emerging in the genomics sector. This doesn't always lead to financial rewards for investors, but several promising genomics stocks could be long-term winners.

Loading paragraph...

Ticker Information Table
Name and ticker	Market cap	Dividend yield	Industry
Natera (NASDAQ:NTRA)	$26.7 billion	0.00%	Biotechnology
Quest Diagnostics (NYSE:DGX)	$20.7 billion	1.75%	Healthcare Providers and Services
Krystal Biotech (NASDAQ:KRYS)	$9.0 billion	0.00%	Biotechnology
Ionis Pharmaceuticals (NASDAQ:IONS)	$12.3 billion	0.00%	Biotechnology
Illumina (NASDAQ:ILMN)	$21.6 billion	0.00%	Life Sciences Tools and Services
CRISPR Therapeutics (NASDAQ:CRSP)	$4.7 billion	0.00%	Biotechnology
10x Genomics (NASDAQ:TXG)	$2.7 billion	0.00%	Life Sciences Tools and Services

Data as of May 16, 2026. Showing 7 of 7 tickers.

Loading ticker_table...

Loading paragraph...

NASDAQ: NTRA

Natera

Today's Change

(-5.36%) $-10.55

Current Price

$186.36

Key Data Points

Market Cap

$27B

Day's Range

$184.81 - $198.65

52wk Range

$131.81 - $256.36

Volume

2.2M

Avg Vol

1.4M

Gross Margin

64.77%

Loading company_card...

Natera (NTRA -5.36%) is an industry leader in cell-free DNA (cfDNA) testing. It focuses on women's health and prenatal testing to detect genetic conditions, as well as tests to detect cancer and monitor organ health. Some of the tests it offers include:

Panorama, a non-invasive prenatal test.
Signatera, a tumor-specific assay for individualized cancer care.
Prospera, a rejection assessment for kidney transplants.

This genomics company has delivered impressive results recently. In 2025, revenue increased 36% to $2.3 billion, and the number of tests processed increased 15% to 3.5 million. Natera is also leveraging artificial intelligence (AI) technology. In August 2025, it launched its own proprietary AI models to drive innovation and enhance clinical decision-making.

Loading paragraph...

2. Quest Diagnostics

Loading paragraph...

NYSE: DGX

Quest Diagnostics

Today's Change

(-0.71%) $-1.33

Current Price

$186.61

Key Data Points

Market Cap

$21B

Day's Range

$186.43 - $189.88

52wk Range

$164.65 - $213.50

Volume

1.1M

Avg Vol

899K

Gross Margin

31.91%

Dividend Yield

1.75%

Loading company_card...

Quest Diagnostics (DGX -0.71%) isn't strictly a genomics stock. It's a diagnostics company with more than 7,700 patient access points, including 2,000 Quest patient service centers. It also offers an extensive menu of over 3,500 tests and a customizable suite of molecular genetic solutions. These include:

Disease-state and specialty-based genomic testing.
RNA sequencing (RNA-seq).
Whole genome sequencing (WGS).
Whole exome sequencing (WES).

One advantage of investing in Quest Diagnostics is that it's in a stronger financial position than most genomics stocks. It's profitable, with net income of $992 million in 2025, up 14% year over year. Revenue was $11 billion, a 12% increase from the prior year. Quest is also one of the better dividend stocks to hold in this industry.

Loading paragraph...

NASDAQ: KRYS

Krystal Biotech

Today's Change

(-3.15%) $-9.98

Current Price

$306.32

Key Data Points

Market Cap

$9.0B

Day's Range

$306.00 - $314.07

52wk Range

$122.80 - $319.48

Volume

13K

Avg Vol

305K

Gross Margin

92.72%

Loading company_card...

Krystal Biotech (KRYS -3.15%) develops genetic medications for rare and serious diseases with limited or no approved therapies. It was the first company to have an FDA-approved therapy for Dystrophic Epidermolysis Bullosa (DEB), a severe skin condition. The FDA approved Krystal Biotech's DEB treatment, Vyjuvek, in 2023.

While Vyjuvek is the company's only approved product to date, it has several other products in its pipeline, including treatments for cystic fibrosis, neurotrophic keratitis, and non-small cell lung cancer. Krystal Biotech has also achieved profitability with just one approved treatment. Net income increased 130% to $205 million in 2025.

Loading paragraph...

4. Ionis Pharmaceuticals

Loading paragraph...

NASDAQ: IONS

Ionis Pharmaceuticals

Today's Change

(-1.92%) $-1.45

Current Price

$74.23

Key Data Points

Market Cap

$12B

Day's Range

$73.32 - $75.93

52wk Range

$32.00 - $86.74

Volume

2.1M

Avg Vol

2.1M

Gross Margin

96.73%

Loading company_card...

Loading paragraph...

NASDAQ: ILMN

Illumina

Today's Change

(-0.49%) $-0.70

Current Price

$142.54

Key Data Points

Market Cap

$22B

Day's Range

$138.06 - $143.86

52wk Range

$78.55 - $155.53

Volume

1.8M

Avg Vol

1.7M

Gross Margin

67.14%

Loading company_card...

Illumina (ILMN -0.49%) develops DNA sequencing and array-based life sciences technologies. Its sequencing technology, sequencing by synthesis (SBS), uses a proprietary method to detect single bases as they're incorporated into growing DNA strands.

Sequencing volumes are growing for research use and clinical applications, including whole-genome sequencing, cancer testing, and recurrence monitoring. Illumina offers several popular sequencing products, most notably its NovaSeq X platform.

While Illumina's revenue has been flat recently, it's a profitable business, with $756 million of net income in 2025. It also completed the acquisition of SomaLogic, a data-driven proteomics company, in January 2026. The move bolsters Illumina's multiomics portfolio and is expected to help the company get back to revenue growth.

Loading paragraph...

6. CRISPR Therapeutics

Loading paragraph...

NASDAQ: CRSP

CRISPR Therapeutics

Today's Change

(-4.04%) $-2.04

Current Price

$48.41

Key Data Points

Market Cap

$4.7B

Day's Range

$48.25 - $50.45

52wk Range

$35.38 - $78.48

Volume

Avg Vol

1.9M

Gross Margin

-528340.24%

Loading company_card...

CRISPR Therapeutics (CRSP -4.04%) develops gene-based medicines using its CRISPR/Cas9 gene editing technology. Along with its partner, Vertex Pharmaceuticals (VRTX -3.02%), CRISPR developed Casgevy (exagamglogene autotemcel), a gene therapy for treating sickle cell disease and beta-thalassemia. It was the first regulatory-approved cell-based gene therapy.

This is high-risk, high-reward, which is par for the course with gene-editing stocks. Revenue is still fairly small at just $3.5 million in 2025, and the company posted a net loss of $582 million. However, CRISPR has a large pipeline that includes hemoglobinopathies, in vivo approaches, and regenerative medicine.

Loading paragraph...

7. 10x Genomics

Loading paragraph...

NASDAQ: TXG

10x Genomics

Today's Change

(-1.49%) $-0.32

Current Price

$21.20

Key Data Points

Market Cap

$2.7B

Day's Range

$20.82 - $21.72

52wk Range

$8.06 - $26.45

Volume

2.7M

Avg Vol

2.5M

Gross Margin

70.49%

Loading company_card...

10x Genomics (TXG -1.49%) develops single-cell and spatial gene sequencing technology. Its primary product lines are the Chromium Single Cell, Visium Spatial, and Xenium In Situ platforms.

Researchers use these platforms to analyze how cells function, identify rare cell types, and observe how cells interact. 10x Genomics' technology has applications across various fields, including oncology, immunology, and pharmaceutical products.

Revenue for 10x Genomics was flat in 2025, but it did take a step toward profitability. It posted a net loss of $44 million, compared to $183 million in 2024.

Loading paragraph...

Investing in genomics stocks FAQ

Loading faq...

About the Author

Lyle Daly is a contributing Motley Fool stock market analyst covering information technology and cryptocurrency. Lyle has been a contributor at the financial services company since 2018. His work has been featured on USA Today, Yahoo Finance, MSN, Fox Business, and Nasdaq. Before joining The Motley Fool, he wrote for financial brands including Intuit.

TMFLyleDaly

@LyleDaly

Lyle Daly has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends 10x Genomics, CRISPR Therapeutics, Ionis Pharmaceuticals, Quest Diagnostics, and Vertex Pharmaceuticals. The Motley Fool recommends Biogen and Illumina. The Motley Fool has a disclosure policy.

Best Genomics Stocks for 2026 and How to Invest

Key Points

Key Data Points

2. Quest Diagnostics

Key Data Points

Key Data Points

4. Ionis Pharmaceuticals

Key Data Points

Key Data Points

6. CRISPR Therapeutics

Key Data Points

7. 10x Genomics

Key Data Points

Related investing topics

Best Healthcare Stocks to Buy in 2026 and How to Invest in Them

Best Growth Stocks to Buy in 2026

Best Health Insurance Stocks for 2026 and How to Invest

Best Biotech Stocks to Buy in 2026 and How to Invest in Them

Investing in genomics stocks FAQ

About the Author

Read Next

Stocks Mentioned

Premium Investing Services

Key Data Points

Best Healthcare Stocks to Buy in 2026 and How to Invest in Them

Best Growth Stocks to Buy in 2026

Best Health Insurance Stocks for 2026 and How to Invest

Best Biotech Stocks to Buy in 2026 and How to Invest in Them

Investing in genomics stocks FAQ

Are genomic stocks a good investment?

Who is the leading genomics company?

Is genomics a growing field?

What is the future of genomic stocks?

What should I look for in a good genomics stock?

Can genomics stocks be part of a diversified portfolio?

Which sectors benefit the most from genomics advancements?

Should beginners invest in genomics stocks?

1. Natera

2. Quest Diagnostics

3. Krystal Biotech

4. Ionis Pharmaceuticals

5. Illumina

6. CRISPR Therapeutics

7. 10x Genomics

How to buy genomics stocks

Benefits and risks of investing in genomics stocks

The bottom line

Related investing topics

FAQ

7 top Genomics stocks for 2026

Key Data Points

Key Data Points

Key Data Points

Key Data Points

Key Data Points

Key Data Points